Although flexible bronchoscopy is the least invasive procedure for sampling, it is limited by its inability to reach lesions in the peripheral segments of the lung. Biopsy success is further compromised if the lesion is less than 30 mm in diameter or cannot be seen on fluoroscopy. We wanted to explore whether a new bronchoscopic navigation system could help access the peripheral lung airways and enable lesion sampling.
A lthough lung cancer incidence is not closely tracked in Europe, in the United States, it is diagnosed in approximately 220,000 people each year and is the leading cause of cancer death (incidence rate 72/100,000). 1 There is an increasing need to evaluate and manage pulmonary nodules and masses in chest medicine. As imaging modalities advance, both computed tomography (CT) and positron emission tomography (PET) are assuming a greater role in lung cancer diagnosis. Imaging with CT is very useful in the evaluation of lung cancer, but it lacks the sensitivity and specificity necessary to definitively establish a diagnosis on its own. Similarly, although PET is more sensitive than CT in identifying lung lesions, there are too many false positives to allow treatment decisions to be consistently made based on PET imaging alone. 2 As a result, although these imaging modalities play a key role in the treatment decisions regarding chemotherapy or surgical resection, often a tissue diagnosis will still be required. 3 Bronchoscopy has been used to evaluate solitary pulmonary nodules (SPNs) and masses for more than 30 years. In patients with such nodules, the diagnostic procedure is usually performed as transbronchial lung biopsy (TBBX) under fluoroscopic guidance. This commonly performed procedure is associated with a low yield in SPNs smaller than 30 mm or lesions that are fluoroscopically invisible. 4 The yield depends not only on the size but also on the location of the abnormality. 5 Nodules that are too small to be visualized by fluoroscopy during bronchoscopy pose a particular problem and usually require more invasive, often surgical, biopsy procedures.
If issues of diagnostic yield could be resolved, flexible bronchoscopy would become the standard in the workup and management of lung lesions. Therefore, new methods are needed for bronchoscopic navigation and lesion localization, which are independent of visualization by fluoroscopy but still dependent on the technical skills of the bronchoscopist. The first promising new technology in this regard was the electromagnetic navigation system (InReach, superDimension Inc., Minneapolis, MN).
There remain some major challenges to the electromagnetic technology. To plan the procedure, the electromagnetic navigation bronchoscopy software is required, and the planning takes some time, up to 10 minutes in trained colleagues. More significantly, the locatable guide is single use and costs between US $700 and $1000, depending on the market, usually without any kind of reimbursement.
Ultrathin bronchoscopes (such as the BF-XP160F; Olympus Medical, Tokyo, Japan), with external diameters of 2.8 mm, have been used in clinical practice since 2004 and can be advanced to more peripheral bronchi than a standard bronchoscope.
Because the bronchoscope can be advanced close to peripheral lesions, subsequent guidance of the forceps is easy. 6 The challenge then becomes to identify the route to a pulmonary peripheral lesion under direct vision within the limited bronchoscopic examination time. 7 It is essential to review the CT images and confirm the bronchoscope's route before performing bronchoscopy. However, it is difficult to obtain a three-dimensional understanding of the complicated tracheobronchial tree based on axial images. Although virtual bronchoscopy (VB) can reconstruct helical CT images to display a three-dimensional rendering resembling the bronchoscopic video, 8 it has rarely been used in bronchoscopy for pulmonary peripheral lesions. 9 VB has some limitations in terms of the actual bronchoscopic procedure. 10 First, the bronchoscope is often rotated while being advanced, creating an offset or shift between the observed actual image and the virtual image. Bronchial branching includes many bifurcations into two bronchi of similar sizes. Therefore, mistakes tend to be made with regard to the correct bronchus into which the bronchoscope will be advanced when there is a marked shift between the observed and VB images. Second, the immediate matching of the VB image corresponding to the observed bronchial branching is difficult when the bronchoscope moves unexpectedly because of patient movements such as coughing. To solve these problems, the LungPoint system displays the VB images adjacent to the actual video, and an electronic pathway is overlaid onto the endoscopic image. Once near the target location, the identified lesion shape is overlaid onto the airway wall on the actual and virtual bronchoscopic images, providing further localization guidance for biopsy.
This article evaluates LungPoint's usefulness as a bronchoscopic navigation system for accessing and sampling pulmonary peripheral lesions.
PATIENTS AND METHODS

Subjects
The subjects were consecutive patients with PET-positive pulmonary peripheral lesions (Ͻ42 mm) and a high suspicion of lung cancer encountered at the Thoraxklinik between July 2009 and December 2009. Lesions with a CT-confirmed pure ground-glass opacity pattern and less than 15 mm were excluded because their diagnosis is considered difficult when biopsy samples only a part of the lesion. The local ethics committee approved this study protocol. All subjects were given detailed descriptions of the examination and were informed that a new approach was being evaluated. Written informed consent was obtained from all subjects.
LungPoint
The LungPoint Virtual Bronchoscopic Navigation System (Broncus Technologies, Inc., Mountain View, CA) is a computer-assisted image-based navigation software that enables the bronchoscopist to navigate and localize a targeted area of interest in the lung. The system requires thin-section volumetric CT scans. CT scan requirements for the system are 1.25-mm slice thickness with an interval spacing of 0.0625 mm or less. Scans at total lung capacity (inspiratory breath-hold) are preferred so that the smaller airways are expanded. The system imports scans in standard Digital Imaging and Communications in Medicine format either from a compact disk or across the network. At our facility, the common parameters for the CT scans were nonenhanced multi-detector computed tomography (4-slice Siemens Volume Zoom, Forchheim, Germany), supine, 70 mAs eff , 120 kV, collimation 4 ϫ 1.25 mm, pitch 2, 1.25-mm slice thickness [typically DLPw ϭ 127 mGy ϫ cm, E ϭ 1.6 mSv according to International Commission on Radiologic Protection], 1-mm increment, B40f algorithm).
These were acquired from a full chest scan during single breath-hold (automatic patient instruction for an inspiratory breath-hold) so that the entry of the lobar bronchus involved by the lesion could be captured. Once the CT study is imported using a compact disk or across the network, the images are automatically analyzed by the LungPoint software. This involves segmenting airways 3 mm and greater in diameter and major vessels by calculating a centerline (central axis) for each airway. Along with airway segmentation, endoluminal renderings of the airway structure are modeled to produce a virtual bronchoscopic view.
We defined the target lesion by placing a three-dimensional spherical marker (from 3 to 30 mm in diameter) on a CT image. The lesion can also be defined using tools to outline it on the CT slice. In this case, the software automatically segments the object in three dimensions. Once the target object is placed, the software calculates up to three pathways through the airways to reach it. These pathways are calculated to reach the points closest to the target. Three-dimensional images of the airway tree and target as well as the virtual bronchoscopic animation enable assessment of the calculated pathways. The CT projections are also available and update as the animation progresses through the airway toward the target.
During bronchoscopy, the navigation system displays two main images: the live bronchoscopic video and the VB animation (Figure 1 ). The animation represents the pathway that was selected during the planning process. An image-based synchronization technique aligns the virtual images with the anatomy seen in the live bronchoscopic video. A "navigator" or "copilot" facilitates this process by advancing and adjusting (rotating or shifting) the virtual bronchoscopic rendering. When the two images are synchronized, the software calculates the position of the bronchoscope in the airway and overlays the pathway to the target on the actual bronchoscopic video image. Adjacent major vessels as well as the target (once it is less than 30 mm away) are overlaid on the airway wall.
Bronchoscopy
TBBX under general anesthesia was performed by a trained bronchoscopist (R.E., F.H.) using a standard (BF-Q180 or BF-1T180; Olympus Medical, Tokyo, Japan) and an ultrathin (BF-XP160F; Olympus Medical) bronchoscope. All samples were taken with 1.2-mm thin biopsy forceps (FB-56D-I; Olympus Medical).
After complete inspection of the bronchial tree, including the subsegmental bronchi, the bronchoscope was navigated using LungPoint as near as possible to the target. After reaching the target or placing the scope in a wedge position, the procedure continued with TBBX in the standard manner without using fluoroscopy. Each lesion was biopsied a minimum of four times.
In case of an inconclusive diagnosis, additional test were performed (e.g., CT-guided fine needle aspiration or thoracoscopy).
Statistical Methods
Diagnostic sensitivity, specificity, and accuracy of the LungPoint-guided transbronchial biopsies were calculated using the standard definitions. Alpha was set at 0.05, and the SPSS statistical software package was used for all analyses (SPSS version 11.5; SPSS, Chicago, IL).
RESULTS
This feasibility trial included 25 subjects (9 women and 16 men) with a mean age of 67 years (SD Ϯ7.5 years; range, 52-83 years) and a mean lesion size of 28 mm (SD Ϯ0.7 mm; range, 18 -42 mm).
Bronchoscopy was performed without complication in all subjects; the mean planning time was 5 minutes (SD Ϯ61 seconds; range, 180 -490 seconds), and the mean examination time was 15 minutes (SD Ϯ2.5 minutes; range, 9 -20 minutes). Scope in to scope out time was 23 minutes (SD Ϯ3.2 minutes; range, 18 -35 minutes). The mean LungPoint navigation time was 5 minutes (SD Ϯ83 seconds; range, 3-8 minutes). The bronchial branchings on the VB images were in good accordance with the actual branching in all cases. In 14 cases (56%), the ultrathin bronchoscope could be advanced under LungPoint guidance into the bronchus of the lesion, and the lesion was visible by the scope. In these situations, further localization of the lesion location was provided by an overlay on the airway wall ( Figure 2 ). For 11 lesions (44%), the ultrathin bronchoscope could only be advanced up to one to two branchings before the lesion location, although the bronchoscope followed the planned route to that point. In these cases, the forceps were advanced beyond the bronchoscope in the direction of the lesion, and a biopsy was taken. In none of the cases, fluoroscopy was used. The scope was held in a fixed position, and the different biopsies were taken. With the standard scope, only six lesions were visible by the scope, so all biopsies were done with the small forceps.
Overall, a diagnosis was established in 20 of the 25 subjects (80%). Among the 20 subjects in whom transbronchial biopsy was diagnostic, 17 of the lesions were classified as malignant (3 cases of squamous cell carcinoma, 11 cases of adenocarcinoma, 1 case of non-small cell lung cancer, 1 case of small cell lung cancer, and 1 case of carcinoma with large cells). Of the diagnostic biopsies, three lesions were classified as benign (one sarcoidosis, one tuberculoma, and one rheumatic nodule). The undiagnosed lesions included one benign (harmatoma) and four malignant lesions. These five cases and the estimated biopsy rheumatic nodule were confirmed by CT-guided needle aspiration (four cases) or surgical biopsies (two cases).
Successfully sampled lesions showed a mean short-axis diameter of 28 mm (SD Ϯ6.5 mm; range, 19 -41 mm). The sensitivity, specificity, and negative and positive predicted values for malignancy were 85%, 100%, 80%, and 57%.
The diagnostic rate depended on whether the lesion was visible with the scope or not. The sampling success rate by subject was 13 of 14 for reached lesions (93%) and 7 of 11 for lesions (63%) beyond the view of the bronchoscope.
In a multivariate analysis, the yield did not depend on the location of the lesion, histology, or other factors (procedure time, planning time, sex, or age).
The mean number of specimens obtained from each nodule was 4.2 (range, 4 -6). Self-limited bleeding was observed in one patient; severe bleeding did not occur. One patient suffered from pneumothorax, but no intervention was necessary. There were no other complications.
DISCUSSION
Bronchoscopy has been used to evaluate SPNs and masses for more than 30 years. Patients with such nodules frequently undergo transbronchial biopsy under fluoroscopic guidance. However, endoscopic transbronchial biopsy often fails to successfully sample lesions smaller than 30 mm or lesions that are fluoroscopically invisible. 4, 12, 13 Nodules too small to be visualized by fluoroscopy usually require additional, often surgical, biopsy procedures.
Therefore, new methods for navigation and localization are needed, which are independent of fluoroscopic visualization and enhance the technical skills of the bronchoscopist. Promising new technologies are CT-based electromagnetic navigation techniques and endobronchial ultrasound (EBUS). Several studies have reported on the efficacy and safety of different techniques. 14 -20 With a diagnostic yield of 80% in our trial, we were able to show quite similar results to the established systems.
Asano et al. 21 published their experience with another prototype of a navigation system. The study subjects included 37 patients with 38 lesions. Using this system, an ultrathin bronchoscope could be advanced into the planned route in 95% of the lesions. A diagnosis was possible for 82% of the lesions.
LungPoint guidance can be performed safely in humans and can easily be incorporated into a flexible bronchoscopy practice. A similar pneumothorax rate compared with fluoroscopic-guided TBBX is shown in this trial. The system may provide not only a reliable means for establishing a tissue diagnosis but also open the door for endoscopic therapeutic management in selected patients. Even though the technology seems very attractive and data are extremely encouraging, more studies establishing yield and best applications are needed.
The use of navigation techniques can push the diagnostic yield of flexible bronchoscopy closer to the sensitivity obtainable with transthoracic CT-guided procedures. Also, pneumothorax, the major risk for transthoracic CT-guided procedures, can be dramatically reduced (from 20 -30% 13 to 3-5% 11 ). The proven comfort and safety of flexible bronchoscopy and the recognized risks of these procedures confirm bronchoscopy with navigation techniques or combined EBUS/navigation as a viable alternative. The combination of navigated bronchoscopy based on a virtual reality and realtime control with the help of EBUS will not only expand the diagnostic possibilities but in the future also provide more therapeutic options for inoperable patients, such as flexible endobronchial radio frequency ablation. The ultimate goal of a reliable and minimally invasive biopsy of peripheral lung lesions now seems feasible.
Some factors of our study need to be acknowledged. It is important to recognize that the prevalence of malignant lesions was high due to the inclusion criteria; therefore, the same results may not be applicable in a more general and unselected population. Another limitation is the small number of patients. The trial was designed as a feasibility trial to prove the concept. One of the major limitations of this study is that no control group is diagnosed by the standard approach of fluoroscopy. Fluoroscopy was not used for navigation, because fluoroscopy is known to be unreliable in the identification of small lesions, and we wanted to ensure that we would collect trial data that is specific for one intervention only, namely LungPoint navigation. Maybe with the use of fluoroscopy, the yield can be increased further. Also, data supporting the use of multiple sampling techniques (needle, bronchiolo alveolaer lavage, and brush) may improve the yield. We limited this study to forceps biopsies for the sake of time.
CONCLUSIONS
For smaller SPNs, navigated bronchoscopy with the LungPoint system seems safe and effective. Navigation support may be more successful than fluoroscopic guidance in sampling small SPNs, increasing the likelihood of a diagnosis and decreasing the need for surgical biopsy. Further studies potentially combining guided approaches with radial EBUS are warranted.
